Kappaproct®

Kappaproct is a DNA-based immunomodulatory sequence (DIMS) and is InDex Pharmaceuticals' lead product for treatment of steroid resistant Ulcerative Colitis (UC).

Phase III
Kappaproct has completed its third clinical phase II trial for the treatment of steroid resistant UC and is now in a phase III clinical trial for treatment refractory UC patients.

Unmet Medical Need
Kappaproct has shown to be efficient when other treatment fails, and to be able to treat patients for whom the only medical option today is highly invasive surgery.

Personalized Medicine
InDex Pharmaceuticals is developing a companion diagnostic to allow selection of patients who are most likely to benefit from treatment with Kappaproct.

Intellectual Property
Kappaproct has IP protection for treatment of inflammatory diseases in US and Europe.

Orphan Drug Status
Kappaproct has recieved Orphan Drug Designation from the European Medicines Agency (EMA).

Kappaproct mechanism of action Click for picture
Kappaproct binds to a receptor called toll-like receptor (TLR) 9 which is located inside target cells of the immune system. This initiates the release of substances, which mediate the beneficial effects seen with Kappaproct for treatment of inflammatory diseases.

Kappaproct enhances the effect of steroids
Kappaproct can very potently increase the effect of steroids and re-sensitize steroid non-responding patients. In this way, the need of taking high doses of steroids, associated with severe side-effects, can be reduced. In addition, Kappaproct has shown to be able to induce long-term steroid free remission.

Excellent safety
Kappaproct has through both clinical studies and animal toxicology studies, in contrast to steroids, proven to have a excellent safety profile.

Many diseases have problem with steroid resistancy
The problem of steroid resistancy is a common phenomenon in many diseases in which Kappaproct also may have very beneficial effects such as asthma, rheumatoid arthritis and leukemia.